Vascular cell adhesion molecule‑1 levels in patients with coronary artery disease with type 2 diabetes mellitus

S.A. Serik; N.R.  Mavrycheva

doi:10.26641/2307-0404.2023.1.276010

Authors

S.A. Serik SI «L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine», Lyubovi Maloy ave., 2а, Kharkiv, 61039, Ukraine https://orcid.org/0000-0001-6257-3566
N.R. Mavrycheva SI «L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine», Lyubovi Maloy ave., 2а, Kharkiv, 61039, Ukraine https://orcid.org/0000-0001-7967-4179

DOI:

https://doi.org/10.26641/2307-0404.2023.1.276010

Keywords:

coronary artery disease, type 2 diabetes mellitus, vascular cell adhesion molecule 1

Abstract

Chronic systemic inflammation is a key component of the pathogenesis of both type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). Soluble vascular cell adhesion molecule‑1 (sVCAM‑1) is considered as the indicator of vascular inflammation and endothelial activation. The aim of our study was to investigate sVCAM‑1 levels in patients with CAD with T2DM and to determine their dependence on a previous history of myocardial infarction (MI). The study included 52 patients with stable CAD with T2DM, 20 CAD patients without diabetes and 14 control group persons. sVCAM-1 levels were measured in serum by the enzyme-linked immunosorbent assay. sVCAM‑1 levels in patients with CAD with T2DM and patients with CAD without diabetes were higher than in the control group (p<0,001 and p<0,001, respectively). The difference in sVCAM‑1 levels between CAD patients with T2DM and without diabetes was not significant (p=0,355). There were no significant correlations of sVCAM‑1 levels with glucometabolic indices in any group. Only in patients with CAD with T2DM sVCAM‑1 level negatively correlated with high-density lipoprotein cholesterol. CAD patients with and without T2DM with a history of myocardial infarction (MI) had higher sVCAM‑1 levels than patients without previous MI (p=0,038, р=0,043, respectively). Only in diabetic CAD patients sVCAM‑1 levels were increased in those without a history of MI (р=0,036, in comparison with the controls). There were no correlations between sVCAM‑1 levels and left ventricular remodeling indices in patients either with or without MI. Conclusions. In patients with CAD with T2DM and patients with CAD without T2DM, sVCAM‑1 levels increased in comparison with the controls. However, in patients without diabetes sVCAM‑1 level was increased only in those with previous MI. In patients with T2DM, sVCAM‑1 level increased in the absence of previous MI and there was the further significant increase of its level in postinfarction cardiosclerosis.

References

Ferrannini G, De Bacquer D, De Backer G, Kot-seva K, Mellbin L, Wood D, et al. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease – A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care. 2020;43(4):726-33. doi: https://doi.org/10.2337/dc19-2165

Mak K, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, et al. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geo-graphical regions and ethnicities. European J of Preventive Cardiology. 2021;28(16):1795-806. doi: https://doi.org/10.1093/eurjpc/zwab011

Hochman J, Reynolds H, Bangalore S, O’Brien S, Alexander K, Senior R, et al. Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology. 2019;4(3):273-86. doi: https://doi.org/10.1001/jamacardio.2019.0014

Nelson A, Peterson E, Pagidipati N. Atheroscle-rotic cardiovascular disease and heart failure: Deter-minants of risk and outcomes in patients with diabetes. Progress in Cardiovascular Diseases. 2019;62(4):306-14. doi: https://doi.org/10.1016/j.pcad.2019.07.001

Newman J, Anthopolos R, Mancini G, Banga-lore S, Reynolds H, Kunichoff D, et al. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation. 2021;144(17):1380-95. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054439

Gholap N, Achana F, Davies M, Ray K, Gray L, Khunti K. Long-term mortality after acute myocardial infarc¬tion among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era. Diabetes, Obesity and Metabolism. 2017;19(3):364-74. doi: https://doi.org/10.1111/dom.12827

Eckel R, Bornfeldt K, Goldberg I. Cardiovascular disease in diabetes, beyond glucose. Cell Metabolism. 2021;33(8):1519-45. doi: https://doi.org/10.1016/j.cmet.2021.07.001

Poznyak A, Grechko A, Poggio P, Myasoedova V, Alfieri V, Orekhov A. The Diabetes Mellitus – Atheroscle-rosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. International J of Molecular Sciences. 2020;21(5):1835. doi: https://doi.org/10.3390/ijms21051835

Sharma A, Mittal S, Aggarwal R, Chauhan M. Diabetes and cardiovascular disease: inter-relation of risk factors and treatment. Future J Pharmaceutical Sciences. 2020;6(1). doi: https://doi.org/10.1186/s43094-020-00151-w

Ministrini S, Carbone F, Montecucco F. Updating concepts on atherosclerotic inflammation: From pathophy¬siology to treatment. European J of Clinical Investigation. 2021;51(5). doi: https://doi.org/10.1111/eci.13467

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe K, et al. Pathophysiology of Type 2 Diabetes Mellitus. International J of Molecular Sciences. 2020;21(17):6275. doi: https://doi.org/10.3390/ijms21176275

Thayse K, Kindt N, Laurent S, Carlier S. VCAM-1 Target in Non-Invasive Imaging for the Detection of Atherosclerotic Plaques. Biology. 2020;9(11):368. doi: https://doi.org/10.3390/biology9110368

Freitas I, Lima N, Silva JrG, Castro JrR, Patel P, Lima C, et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Revista Portuguesa de Cardiologia. 2020;39(11):667-72. doi: https://doi.org/10.1016/j.repc.2020.05.010

Storti F, Pulley J, Kuner P, Abt M, Luhmann U. Circulating Biomarkers of Inflammation and Endothelial Activation in Diabetic Retinopathy. Translational Vision Science & Technology. 2021;10(12):8. doi: https://doi.org/10.1167/tvst.10.12.8

Hayek A, Paccalet A, Mechtouff L, Da Silva C, Ivanes F, Falque H, et al. Kinetics and prognostic value of soluble VCAM‐1 in ST‐segment elevation myocardial infarction patients. Immunity, Inflammation and Disease. 2021;9(2):493-501. doi: https://doi.org/10.1002/iid3.409

Palella E, Cimino R, Pullano S, Fiorillo A, Gulletta E, et al. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. International J of Environmental Research and Public Health. 2020;17(1):300. doi: https://doi.org/10.3390/ijerph17010300

Antuna-Puente B, Disse E, Rabasa-Lhoret R, La-ville M, Capeau J, Bastard J. How can we measure insulin sensitivity/resistance?. Diabetes & Metabolism. 2011;37(3):179-88. doi: https://doi.org/10.1016/j.diabet.2011.01.002

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart J. 2019;41(1):111-88. doi: https://doi.org/10.1093/eurheartj/ehz455

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J of the American Society of Echocardiography. 2015;28(1):1-39.e14. doi: https://doi.org/10.1016/j.echo.2014.10.003

Antomonov MYu. [Mathematical processing and analysis of medical and biological data]. 2nd ed. Kyiv: Medinform; 2017. 578 p. Russian.

Hegazy G, Awan Z, Hashem E, Al-Ama N, Abunaji A. Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications. J of International Medical Research. 2019;48(4):030006051989385. doi: https://doi.org/10.1177/0300060519893858

Fadel M, Abdel Ghaffar F, Zwain S, Ibrahim H, Badr E. Serum netrin and VCAM-1 as biomarker for Egyptian patients with type IΙ diabetes mellitus. Biochemistry and Biophysics Reports. 2021;27:101045. doi: https://doi.org/10.1016/j.bbrep.2021.101045

Hocaoglu-Emre F, Saribal D, Yenmis G, Guvenen G. Vascular Cell Adhesion Molecule 1, Intercellular Adhesion Molecule 1, and Cluster of Differentiation 146 Levels in Patients with Type 2 Diabetes with Complications. Endocrinology and Metabolism. 2017;32(1):99. doi: https://doi.org/10.3803/EnM.2017.32.1.99

Joy N, Mikeladze M, Younk L, Tate D, Davis S. Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism. 2016;65(12):1695-705. doi: https://doi.org/10.1016/j.metabol.2016.09.001

Su Q, Zhang L, Qi Z, Huang B. The Mechanism of Inflammatory Factors and Soluble Vascular Cell Adhesion Molecule-1 Regulated by Nuclear Transcription Factor NF-κB in Unstable Angina Pectoris. J of Immunology Research. 2022;2022:1-8. doi: https://doi.org/10.1155/2022/6137219

Denimal D, Benanaya S, Monier S, Simoneau I, Pais de Barros J, Le Goff W, et al. Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities. J of Clinical Endocrinology & Metabolism. 2022;107(9):e3816-23. doi: https://doi.org/10.1210/clinem/dgac339

Hulok A, Ściborski K, Marczak J, Bańkowski T, Poręba R, Negrusz-Kawecka M. Soluble Cell Adhesion Molecules – Does Estimating sVCAM-1 and sICAM-1 Concentration Provide Additional Information About Cardiovascular Risk in Patients with Coronary Artery Disease? Advances in Clinical and Experimental Medicine. 2014;23(5):735-41. doi: https://doi.org/10.17219/acem/37232